28A-1120309
Preclinical research and clinical trials have demonstrated the potential efficacy of primary retinal progenitor cells (RPCs) derived from embryonic tissue in treating late-stage degenerative retinal diseases. However, the use of primary RPCs often involves ethical and moral controversies due to their origin from fetal tissues. To address this issue, we have developed a method using six small-molecule drugs to directly reprogram human fibroblasts into chemically induced retinal progenitor-like cells (CiRPCs).
- CiRPCs offer the potential to restore both color and monochromatic vision in patients.
- The conversion efficiency of CiRPCs in this technology reaches up to 42.8%.
- The differentiation of CiRPCs requires only five days.
- This technology does not require the use of any carcinogenic viral insertions.
- CiRPCs are suitable for both autologous and allogeneic transplantation, enhancing treatment flexibility.
- Chemically induced retinal progenitor like cells (CiRPCs) can be applied in cell replacement therapy to treat degenerative retinal diseases such as retinitis pigmentosa (RP), age-related macular degeneration (AMD), and diabetic retinopathy (DR).
- The small-molecule drug components used in this technology can also be applied to develop other types of chemically induced cells for the treatment of neurodegenerative diseases.
Lu, Joyce Jean
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Direct Reprogramming of Human Fibroblasts into Retinal Progenitor Cells